Prof Jake Shortt
Clinical (Professor)
The Sir Peter MacCallum Department of Oncology
251 Scholarly works
5 Projects
HIGHLIGHTS
2026
Journal article
Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
DOI: 10.1158/1535-7163.MCT-25-03062026
Journal article
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia.
DOI: 10.1182/bloodadvances.20250175752026
Journal article
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia
DOI: 10.1111/bjh.702762025
Journal article
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations
DOI: 10.1182/blood.20250302592025
Journal article
Insights from the largest diverse ancestry sex-specific disease map for genetically predicted height
DOI: 10.1038/s41525-025-00464-w2018
Research Grant
Targeting Transcriptional Addiction for Cancer Therapy.
2017
Research Grant
Exploiting and Defining the Immune Regulatory Activities of Bet Bromodomain Inhibitors
RECENT SCHOLARLY WORKS
2025
Journal article
Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury
DOI: 10.1093/jac/dkaf2992025
Journal article
Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus
DOI: 10.1038/s43856-025-00863-12025
Journal article
EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort
DOI: 10.1182/blood-2025-522025
Journal article
P300/CBP acetyltransferase inhibition and degradation disrupt oncogenic transcriptional programs and reveal epigenetic vulnerabilities in multiple myeloma
DOI: 10.1182/blood-2025-57172025
Journal article
Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial
DOI: 10.1182/blood-2025-792
RECENT PROJECTS
2014
Research Grant
Awakening Dormant Genes to Help the Immune System Fight Blood Cancers
2015
Research Grant
Discovery of New Treatments for Therapy-Resistant Multiple Myeloma.
2015
Research Grant
Overcoming Resistance to Bromodomain Inhibition in Myc-Driven Lymphoma